Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

NASHVILLE, Tenn. (WSMV) - Vanderbilt University Medical Center will lead a massive project aimed at discovering therapeutic antibodies through the use of Artificial Intelligence. Therapeutic ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

Research shows multiple factors drive CKD risk in lupus nephritis, including nephritic flares, baseline hypertension, renal ...

* From the Critical Care Department (Dr. Dimopoulos), "Attikon" University Hospital, Athens, Greece; and Alfa Institute of Biomedical Sciences (Drs. Siempos, Korbila, Manta, and Falagas), Athens ...

Two reviewers (IPK and KGM) independently searched the aforementioned databases to identify potentially eligible trials. To be included in our analysis, a trial had to be an RCT, and to focus on ...

(It may have led to my serious osteoporosis.) A biopsy revealed totally flattened villi. I am gluten-free and will be getting celiac-antibody, nutrient and other regular lab work from now on. But my ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.